Take this FAST ACTION today: Register for the 2nd Annual Angelman Syndrome Congressional Advocacy Day on March 4-5th, 2025 in Washington, DC.

Read more about AS Congressional Advocacy Day below.

We are 7 days away from the Externally Led Patient Focused Drug Development (EL-PFDD) meeting on Wednesday, January 29.

View the agenda and submit your comments early to the FDA:

Our 2nd Angelman Syndrome Congressional Advocacy Day in Washington, DC will be here before we know it. We hope you can join us for this 2-day event March 4-5th, 2025.  

On Day 1, advocates will attend an advocate training. On Day 2, advocates head to Capitol Hill for meetings with your state’s congressional representatives and senators (or staffers) – the chance to tell your story!

Frequently Asked Questions • Book hotel by Feb 11th

FAST is thrilled to announce the launch of the Innovation Seed Grant. This new funding opportunity is designed to give researchers the resources they need to collect the initial data that could open the door to future larger-scale funding opportunities. 

Learn more about this grant:

The Roadmap to a Cure is the backbone of FAST’s mission. To enable families, researchers and clinicians to better visualize and understand that Roadmap, FAST has launched the Angelman Syndrome Drug Development Pipeline. This interactive tool provides a comprehensive overview and insight into the current programs, aka “shots on goal”, that are in the pipeline, as we work towards an approved therapeutic for individuals living with Angelman syndrome. 

Visit the pipeline and try out our tool:

Joelene Wand, mother of Jude, who lives with AS, recently published an article in Angelman Syndrome News highlighting her first time attending the Global Science Summit & Gala. Joelene, along with her husband Tom, have become active members in the AS community in Australia and beyond, in just the first months of Jude being diagnosed.  

Read more about Joelene’s story:

Thanks for reading, and please share this email with anyone in your network who would be interested in receiving our updates.